Association between Empagliflozin Use and Electrocardiographic Changes

Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patie...

Full description

Saved in:
Bibliographic Details
Published inClinics and practice Vol. 12; no. 4; pp. 557 - 564
Main Authors Antwi-Amoabeng, Daniel, Sathappan, Sunil, Beutler, Bryce D., Ulanja, Mark B., Awad, Munadel, Gullapalli, Nageshwara, Duncan, Phillip, Gbadebo, T. David
Format Journal Article
LanguageEnglish
Published Bari MDPI AG 15.07.2022
MDPI
Subjects
Cardiac arrhythmia
Cardiology
Clinical trials
Comorbidity
Diabetes
Drug dosages
Ejection fraction
Electrocardiography
empagliflozin
Females
Heart failure
Hospitalization
late sodium channel
SGLT2 inhibitors
Sodium
Online AccessGet full text

Cover

More Information
Summary:Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.
ISSN:2039-7283
2039-7275
2039-7283
DOI:10.3390/clinpract12040059